Won-Jung Koh

Won-Jung Koh

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
JIJakko van Ingen
Jakko van Ingen
TATimothy Aksamit
Timothy Aksamit
CAClaire Andrejak
Claire Andrejak
EBErik C. Böttger
Erik C. Böttger
ECEmmanuelle Cambau
Emmanuelle Cambau
DWDirk Wagner
Dirk Wagner
Improving treatment outcome reporting in NTM disease: NTM-NET (@ntmnet) consensus statement on treatment outcome definitionshttp://ow.ly/c6IC30iwLM4

17 March 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
NKNakwon Kwak
Nakwon Kwak
MDMargareth Pretti Dalcolmo
Margareth Pretti Dalcolmo
CDCharles L. Daley
Charles L. Daley
GEGeoffrey Eather
Geoffrey Eather
RGRegina Gayoso
Regina Gayoso
JYJae-Joon Yim
Jae-Joon Yim
Treatment ofMycobacterium abscessuspulmonary disease (MAB-PD), caused byM. abscessussubsp.abscessus,M. abscessussubsp.massilienseorM. abscessussubsp.bolletii, is challenging.We conducted an individual patient data meta-analysis based on studies reporting treatment outcomes for MAB-PD to clarify treatment outcomes for MAB-PD and the impact of each drug on treatment outcomes. Treatment success was defined as culture conversion for ≥12 months while on treatment or sustained culture conversion without relapse until the end of treatment.Among 14 eligible studies, datasets from eight studies were provided and a total of 303 patients with MAB-PD were included in the analysis. The treatment success rate across all patients with MAB-PD was 45.6%. The specific treatment success rates were 33.0% forM. abscessussubsp.abscessusand 56.7% forM. abscessussubsp.massiliense. For MAB-PD overall, the use of imipenem was associated with treatment success (adjusted odds ratio (aOR) 2.65, 95% CI 1.36–5.10). For patients withM. abscessussubsp.abscessus, the use of azithromycin (aOR 3.29, 95% CI 1.26–8.62), parenteral amikacin (aOR 1.44, 95% CI 1.05–1.99) or imipenem (aOR 7.96, 95% CI 1.52–41.6) was related to treatment success. For patients with M. abscessussubsp.massiliense, the choice among these drugs was not associated with treatment outcomes.Treatment outcomes for MAB-PD are unsatisfactory. The use of azithromycin, amikacin or imipenem was associated with better outcomes for patients withM. abscessussubsp.abscessus.

10 November 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
WKWon-Jung Koh
Won-Jung Koh
Byeong-Ho JeongByeong-Ho Jeong
Byeong-Ho Jeong
SKSu-Young Kim
Su-Young Kim
KJKyeongman Jeon
Kyeongman Jeon
KPKyoung Un Park
Kyoung Un Park
OKO Jung Kwon
O Jung Kwon
Treatment outcomes of patients with Mycobacterium abscessus subspecies abscessus lung disease are poor, and the microbial characteristics associated with treatment outcomes have not been studied systematically. The purpose of this study was to identify associations between microbial characteristics and treatment outcomes in patients with M. abscessus lung disease. Sixty-seven consecutive patients with M. abscessus lung disease undergoing antibiotic treatment for ≥12 months between January 2002 and December 2012 were included. Morphotypic and genetic analyses were performed on isolates from 44 patients. Final sputum conversion to culture negative occurred in 34 (51%) patients. Compared to isolates from 24 patients with persistently positive cultures, pretreatment isolates from 20 patients with final negative conversion were more likely to exhibit smooth colonies (9/20, 45% vs 2/24, 8%; P = .020), susceptibility to clarithromycin (7/20, 35% vs 1/24, 4%; P = .015), and be of the C28 sequevar with regard to the erm(41) gene (6/20, 30% vs 1/24, 4%; P = .035). Mycobacterium abscessus lung disease recurred in 5 (15%) patients after successful completion of antibiotic therapy. Genotypic analysis revealed that most episodes (22/24, 92%) of persistently positive cultures during antibiotic treatment and all cases of microbiologic recurrence after treatment completion were caused by different M. abscessus genotypes within a patient. Precise identification to the subspecies level and analysis of mycobacterial characteristics could help predict treatment outcomes in patients with M. abscessus lung disease. Treatment failures and recurrences are frequently associated with multiple genotypes, suggesting reinfection. NCT00970801.

27 September 2017 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
WKWon-Jung Koh
Won-Jung Koh
SMSeong Mi Moon
Seong Mi Moon
SKSu-Young Kim
Su-Young Kim
MWMin-Ah Woo
Min-Ah Woo
SKSeonwoo Kim
Seonwoo Kim
OKO Jung Kwon
O Jung Kwon
The effect of the clinical phenotype ofMycobacterium aviumcomplex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481 patients, 278 (58%) had noncavitary nodular bronchiectatic (NB) disease, 80 (17%) had cavitary NB disease and 123 (25%) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88%) than in patients with cavitary disease (76% for fibrocavitary and 78% for cavitary NB disease; p<0.05). Cavitary disease was independently associated with unfavourable outcomes (p<0.05). Out of 402 patients with favourable outcomes, 118 (29%) experienced redevelopment of NTM lung disease, with the same MAC species recurring in 65 (55%) patients. The NB form was an independent risk factor for redevelopment of NTM lung disease (p<0.05). In patients with recurrent MAC lung disease due to the same species, bacterial genotyping revealed that 74% of cases were attributable to reinfection and 26% to relapse.Treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by clinical phenotype of MAC lung disease.

1 December 2012 in Chest
Verified
Journal Article
Closed access
WKWon-Jung Koh
Won-Jung Koh
Byeong-Ho JeongByeong-Ho Jeong
Byeong-Ho Jeong
KJKyeongman Jeon
Kyeongman Jeon
NLNam Yong Lee
Nam Yong Lee
KLKyung Soo Lee
Kyung Soo Lee
OKO. Jung Kwon
O. Jung Kwon

24 February 2017 in Microbiology Spectrum
Verified
Journal Article
Closed access
WKWon-Jung Koh
Won-Jung Koh
Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both immunocompromised and immunocompetent patients. The development of molecular methods has allowed the characterization of new species and the identification of NTM to the precise species and subspecies levels. The incidence and prevalence of NTM lung disease are increasing worldwide, and this syndrome accounts for the majority of clinical cases of NTM disease. Common causative organisms of pulmonary infection are the slowly growing mycobacteria Mycobacterium avium complex and Mycobacterium kansasii and the rapidly growing mycobacteria, including Mycobacterium abscessus complex. NTM lung disease often affects elderly people with chronic lung disease and may be a manifestation of a complex genetic disorder determined by interactions among multiple genes, as well as environmental exposures. To be diagnosed with NTM lung disease, patients should meet all clinical and microbiologic criteria, but the decision to start treatment is complex, requiring careful individualized analysis of risks and benefits. Clinicians should be alert to the unique aspects of NTM lung disease, including the need for proper diagnosis, the availability of advanced molecular methods for species and subspecies identification, and the benefits and limitations of recommended treatments.